Cargando…

Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice

Dysfunction of glucagon-secreting α-cells participates in the progression of diabetes, and glucagon receptor (GCGR) antagonism is regarded as a novel strategy for diabetes therapy. GCGR antagonism upregulates glucagon and glucagon-like peptide 1 (GLP-1) secretion and, notably, promotes β-cell regene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Tianjiao, Cui, Xiaona, Jiang, Yafei, Wang, Kangli, Wang, Dandan, Li, Fei, Lin, Xiafang, Gu, Liangbiao, Yang, Kun, Yang, Jin, Hong, Tianpei, Wei, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2023
Materias:	Islet Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130488/ https://www.ncbi.nlm.nih.gov/pubmed/36826938 http://dx.doi.org/10.2337/db22-0784

Ejemplares similares

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
por: Lang, Shan, et al.
Publicado: (2020)

Pro-α-cell-derived β-cells contribute to β-cell neogenesis induced by antagonistic glucagon receptor antibody in type 2 diabetic mice
por: Cui, Xiaona, et al.
Publicado: (2022)

Glucagon Receptor Antagonist–Stimulated α-Cell Proliferation Is Severely Restricted With Advanced Age
por: Lam, Carol J., et al.
Publicado: (2019)

EphA4 Receptor Forward Signaling Inhibits Glucagon Secretion From α-Cells
por: Hutchens, Troy, et al.
Publicado: (2015)

A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor
por: Al-Zamel, Noura, et al.
Publicado: (2019)

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
por: Sloop, Kyle W., et al.
Publicado: (2010)

Glucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia
por: Bozadjieva Kramer, Nadejda, et al.
Publicado: (2021)

Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice
por: Galsgaard, Katrine D., et al.
Publicado: (2022)

Mitochondrial GTP Insensitivity Contributes to Hypoglycemia in Hyperinsulinemia Hyperammonemia by Inhibiting Glucagon Release
por: Kibbey, Richard G., et al.
Publicado: (2014)

Glucose Controls Glucagon Secretion by Regulating Fatty Acid Oxidation in Pancreatic α-Cells
por: Armour, Sarah L., et al.
Publicado: (2023)

Antagonistic Glucagon Receptor Antibody Promotes α-Cell Proliferation and Increases β-Cell Mass in Diabetic Mice
por: Wei, Rui, et al.
Publicado: (2019)

Glucagon-Like Peptide 1 Inhibits the Sirtuin Deacetylase SirT1 to Stimulate Pancreatic β-Cell Mass Expansion
por: Bastien-Dionne, Pierre-Olivier, et al.
Publicado: (2011)

Combination Therapy With Glucagon-Like Peptide-1 and Gastrin Restores Normoglycemia in Diabetic NOD Mice
por: Suarez-Pinzon, Wilma L., et al.
Publicado: (2008)

Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure
por: Gao, Chen, et al.
Publicado: (2019)

Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1–Stimulated Postprandial Insulin Secretion in Humans
por: Salehi, Marzieh, et al.
Publicado: (2011)

Normal Glucagon Signaling and β-Cell Function After Near-Total α-Cell Ablation in Adult Mice
por: Thorel, Fabrizio, et al.
Publicado: (2011)

In Situ Electrophysiological Examination of Pancreatic α Cells in the Streptozotocin-Induced Diabetes Model, Revealing the Cellular Basis of Glucagon Hypersecretion
por: Huang, Ya-Chi, et al.
Publicado: (2013)

Pancreatic alpha cell glucagon–liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes
por: Cui, Xiaona, et al.
Publicado: (2022)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Membrane Potential-Dependent Inactivation of Voltage-Gated Ion Channels in α-Cells Inhibits Glucagon Secretion From Human Islets
por: Ramracheya, Reshma, et al.
Publicado: (2010)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor
por: Hennen, Stephanie, et al.
Publicado: (2016)

Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice
por: Lafferty, Ryan A, et al.
Publicado: (2022)

Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
por: Zhao, Fenghui, et al.
Publicado: (2022)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
por: Xu, Dan, et al.
Publicado: (2022)

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
por: Unger, Jeffrey R., et al.
Publicado: (2011)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021)

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
por: Tanday, Neil, et al.
Publicado: (2021)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
por: Cheng, Dihe, et al.
Publicado: (2022)

Correction: Al-Zamel, N., et al. A Dual GLP-1/GIP Receptor agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased agonist at the GLP-1 Receptor. Int. J. Mol. Sci. 2019, 20, 3532
por: Al-Zamel, Noura, et al.
Publicado: (2020)

Conformational states of the full-length glucagon receptor
por: Yang, Linlin, et al.
Publicado: (2015)

Somatostatin Receptor Type 2 Antagonism Improves Glucagon Counterregulation in Biobreeding Diabetic Rats
por: Karimian, Negar, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nui08tl06b1bvpbrjica8307ut